X-linked adrenoleukodystrophy: literature review, description of clinical cases
V. A. Alekseeva,
A. V. Gavrichenko,
A. A. Yakovlev,
M. G. Sokolova,
E. R. Barancevich,
A. P. Abramova https://doi.org/10.24884/1607-4181-2025-32-2-100-112
Abstract
X-linked adrenoleukodystrophy (X-ALD) is an orphan hereditary disease belonging to the group of peroxisomal diseases with an X-linked recessive type of inheritance, associated with mutations in the ABCD1 gene, characterized by combined damage to the nervous system and adrenal glands. The article provides a review of the literature on this nosology with a description of the etiopathogenesis, clinical picture, diagnostic methods, differential diagnosis and treatment options for this disease. The article describes clinical cases of three patients who were hospitalized in the neurological department № 2 of Pavlov University between 2018 and 2024, based on their complaints, neurological examination data, and laboratory and instrumental diagnostic methods, they were diagnosed with X-ALD. In all the presented clinical cases, more than 3 years passed from the onset of the first symptoms to the final diagnosis, which is due to the difficulty of diagnosing X-ALD at early stages due to the polymorphism of the clinical picture: from classical manifestations of encephalopathy to infrequently encountered manifestations of myelopathy and polyneuropathic syndrome in this nosology. In this regard, timely diagnosis of the disease is important, since effective disease-modifying treatment methods can only be effective if therapy is started in a timely manner.
About the Authors
V. A. Alekseeva
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Alekseeva Viktoriya A., Clinical Resident of the Department of Neurology and Manual Medicine, Faculty of Postgraduate Education
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
A. V. Gavrichenko
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Gavrichenko Artur V., Cand. Sci. (Med.), Neurologist of the Neurological Department № 2 of the Clinic of the Research Institute of Neurology
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
A. A. Yakovlev
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Yakovlev Alexey A., Cand. Sci. (Med.), Head of the Neurological Department № 2 of the Clinic of the Research Institute of Neurology
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
M. G. Sokolova
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Sokolova Mariya G., Dr. Sci. (Med.), Associate Professor, Professor of the Department of Neurosurgery
197341, St. Petersburg, Akkuratova str., 2
Competing Interests:
Authors declare no conflict of interest.
E. R. Barancevich
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Barancevich Evgenii R., Dr. Sci. (Med.), Professor, Head of the Department of Neurology and Manual Medicine, Faculty of Postgraduate Education
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
A. P. Abramova
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
Abramova Anna P., Neurologist, Neurological Department № 2
197341, St. Petersburg, Akkuratova str., 2
Competing Interests:
Authors declare no conflict of interest.
References
1. Engelen M., Kemp S., de Visser M. et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management // Orphanet Journal of Rare Diseases. 2012;7(1):51. http://dx.doi.org/10.1186/1750-1172-7-51.
2. Kemp S., Theodoulou F. L., Wanders R. J. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance // British Journal of Pharmacology. 2011;164(7):1753–66. http://dx.doi.org/10.1111/j.1476-5381.2011.01435.x.
3. Sarde C. O., Mosser J., Kioschis P. et al. Genomic Organization of the Adrenoleukodystrophy Gene // Genomics. 1994;22(1):13–20. http://dx.doi.org/10.1006/geno.1994.1339.
4. Ma C. Y., Li C., Zhou X. et al. Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies // Biomedicine &: Pharmacotherapy. 2021;143:112214. http://dx.doi.org/10.1016/j.biopha.2021.112214.
5. Ofman R., Dijkstra I. M. E., van Roermund C. W. T. et al. The role of ELOVL1 in very long‐chain fatty acid homeostasis and X‐linked adrenoleukodystrophy // EMBO Molecular Medicine. 2010;2(3):90–7. http://dx.doi.org/10.1002/emmm.201000061.
6. Fourcade S., Lopez-Erauskin J., Galino J. et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy // Human Molecular Genetics. 2008;17(12):1762– 73. http://dx.doi.org/10.1093/hmg/ddn085.
7. Petrillo S., Piemonte F., Pastore A. et al. Glutathione imbalance in patients with X-linked adrenoleukodystrophy // Molecular Genetics and Metabolism. 2013;109(4):366–70. http://dx.doi.org/10.1016/j.ymgme.2013.05.009.
8. Weinhofer I., Rommer P., Gleiss A. et al. Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy // eBioMedicine. 2023;96:104781. http://dx.doi.org/10.1016/j.ebiom.2023.104781.
9. Kemp S., Huffnagel I. C., Linthorst G. E. et al. Adrenoleukodystrophy – neuroendocrine pathogenesis and redefinition of natural history // Nature Reviews Endocrinology. 2016;12(10):606–15. http://dx.doi.org/10.1038/nrendo.2016.90.
10. Moser H. W., Mahmood A., Raymond G. V. X-linked adrenoleukodystrophy. Nature Clinical Practice Neurology. 2007;3(3):140–51. http://dx.doi.org/10.1038/ncpneuro0421.
11. Korenke G. C., Pouwels P. J. W., Frahm J. et al. Arrested cerebral adrenoleukodystrophy: A clinical and proton magnetic resonance spectroscopy study in three patients // Pediatric Neurology. 1996;15(2):103–7. http://dx.doi.org/10.1016/0887-8994(95)00156-5.
12. Turk B. R., Theda C., Fatemi A., Moser A. B. X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies // International Journal of Developmental Neuroscience. 2020;80(1):52–72. http://dx.doi.org/10.1002/jdn.10003.
13. Dubey P., Raymond G. V., Moser A. B. et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening //The Journal of Pediatrics. 2005;146(4):528–32. http://dx.doi.org/10.1016/j.jpeds.2004.10.067.
14. Kemp S., Berger J., Aubourg P. X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2012;1822(9):1465–74. http://dx.doi.org/10.1016/j.bbadis.2012.03.012.
15. Papini M., Calandra P., Calvieri S. et al. Adrenoleucodystrophy: Dermatological Findings and Skin Surface Lipid Study // Dermatology. 1994;188(1):25–7. http://dx.doi.org/10.1159/000247080.
16. Assies J., Gooren L. J. G., Geel B. V., Barth P. G. Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X‐linked adrenoleukodystrophy: a retrospective study // International Journal of Andrology. 1997;20(5):315–21. http://dx.doi.org/10.1046/j.1365-2605.1997.00066.x.
17. Brennemann W., Kohler W., Zierz S., Klingmuller D. Testicular dysfunction in adrenomyeloneuropathy // European Journal of Endocrinology. 1997;137(1):34–9. http://dx.doi.org/10.1530/eje.0.1370034.
18. Karapanou O., Vlassopoulou B., Tzanela M. et al. X-linked adrenoleukodystrophy: are signs of hypogonadism always due to testicular failure? // Hormones. 2014;13(1):146– 52. http://dx.doi.org/10.1007/bf03401330.
19. Engelen M., Barbier M., Dijkstra I. M. E. et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study // Brain. 2014;137(3):693–706. http://dx.doi.org/10.1093/brain/awt361.
20. Huffnagel I. C., Dijkgraaf M. G. W., Janssens G. E. et al. Disease progression in women with X-linked adrenoleukodystrophy is slow // Orphanet Journal of Rare Diseases. 2019 Feb 7;14(1):30. http://dx.doi.org/10.1186/s13023-019-1008-6.
21. Van der Knaap M. S., Valk J. Magnetic Resonance of Myelination and Myelin Disorders // Springer Berlin Heidelberg. 2005:176–190. http://dx.doi.org/10.1007/3-540-27660-2.
22. Liberato A. P., Mallack E. J., Aziz-Bose R. et al. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy // Neurology. 2019;92(15):e1698–e1708. http://dx.doi.org/10.1212/wnl.0000000000007294.
23. Musolino P. L., Gong Y., Snyder J. M. T. et al. Brain endothelial dysfunction in cerebral adrenoleukodystrophy // Brain. 2015;138(11):3206–20. http://dx.doi.org/10.1093/brain/awv250.
24. van Geel B. M., Koelman J. H. T. M., Barth P. G. et al. Peripheral nerve abnormalities in adrenomyeloneuropathy // Neurology. 1996;46(1):112–8. http://dx.doi.org/10.1212/wnl.46.1.112.
25. Chaudhry V., Moser H. W., Cornblath D. R. Nerve conduction studies in adrenomyeloneuropathy // Journal of Neurology, Neurosurgery&Psychiatry. 1996;61(2):181–5. http://dx.doi.org/10.1136/jnnp.61.2.181.
26. Engelen M., van der Kooi A. J., Kemp S. et al. X-linked adrenomyeloneuropathy due to a novel missense mutation in the ABCD1 start codon presenting as demyelinating neuropathy // Journal of the Peripheral Nervous System. 2011;16(4):353–5. http://dx.doi.org/10.1111/j.1529-8027.2011.00367.x.
27. Zhu J., Eichler F., Biffi A. et al. The Changing Face of Adrenoleukodystrophy // Endocrine Reviews. 2020;41(4):577– 93. http://dx.doi.org/10.1210/endrev/bnaa013.
28. Gupta A. O., Raymond G., Pierpont E. I. et al. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy // Expert Opinion on Biological Therapy. 2022;22(9):1151–62. http://dx.doi.org/10.1080/14712598.2022.2124857.
29. Raymond G. V., Aubourg P., Paker A. et al. Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation // Biology of Blood and Marrow Transplantation. 2019;25(3):538–48. http://dx.doi.org/10.1016/j.bbmt.2018.09.036.
30. Shapiro E., Krivit W., Lockman L. et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy // The Lancet. 2000;356(9231):713–8. http://dx.doi.org/10.1016/s0140-6736(00)02629-5.
31. Miller W. P., Rothman S. M., Nascene D. et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report // Blood. 2011;118(7):1971–8. http://dx.doi.org/10.1182/blood-2011-01-329235.
32. Cartier N., Hacein-Bey-Abina S., Bartholomae C. C. et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy // Science. 2009;326(5954):818–23. http://dx.doi.org/10.1126/science.1171242.
33. Moser H. W., Moser A. B., Hollandsworth K. et al. “Lorenzo’s Oil” Therapy for X-linked Adrenoleukodystrophy: Rationale and Current Assessment of Efficacy // Journal of Molecular Neuroscience. 2007;33(1):105–13. http://dx.doi.org/10.1007/s12031-007-0041-4.
34. Ahmed M. A., Kartha R. V., Brundage R. C. et al. A model‐based approach to assess the exposure–response relationship of Lorenzo’s oil in adrenoleukodystrophy // British Journal of Clinical Pharmacology. 2016;81(6):1058–66. http://dx.doi.org/10.1111/bcp.12897.
35. Singh I., Khan M., Key L., Pai S. Lovastatin for X-Linked Adrenoleukodystrophy // New England Journal of Medicine. 1998;339(10):702–3. http://dx.doi.org/10.1056/nejm199809033391012.
36. Engelen M., Ofman R., Dijkgraaf M. G. W. et al. Lovastatin in X-Linked Adrenoleukodystrophy // New England Journal of Medicine. 2010;362(3):276–7. http://dx.doi.org/10.1056/nejmc0907735.
37. Fourcade S., Goicoechea L., Parameswaran J. et al. High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy // Brain Pathology. 2020;30(5):945–63. http://dx.doi.org/10.1111/bpa.12869.
38. Casasnovas C., Ruiz M., Schlüter A. et al. Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study // Neurotherapeutics. 2019;16(4):1167–82. http://dx.doi.org/10.1007/s13311-019-00735-2.
39. Ranea‐Robles P., Launay N., Ruiz M. et al. Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy// EMBO Molecular Medicine. 2018;10(8):e8604. http://dx.doi.org/10.15252/emmm.201708604.
40. Wong S. H., Boggild M., Enevoldson T. P., Fletcher N. A. Myelopathy but normal MRI: where next?// Practical Neurology. 2008;8(2):90–102. http://dx.doi.org/10.1136/jnnp.2008.144121.
Review
For citations:
Alekseeva V.A., Gavrichenko A.V., Yakovlev A.A., Sokolova M.G., Barancevich E.R., Abramova A.P. X-linked adrenoleukodystrophy: literature review, description of clinical cases. The Scientific Notes of the Pavlov University. 2025;32(2):100-112. (In Russ.) https://doi.org/10.24884/1607-4181-2025-32-2-100-112
Views:
4
Email this article 